Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$4.84 -0.4%	$4.37	$2.94 ▼ $10.25	$269.79M	3.04	142,780 shs	870,126 shs
NTLA Intellia Therapeutics	$9.56 -0.5%	$8.56	$5.90 ▼ $28.18	$990.25M	2.14	2.92 million shs	4.00 million shs
SYRE Spyre Therapeutics	$15.22 -5.0%	$15.25	$10.91 ▼ $40.26	$917.40M	2.72	580,546 shs	2.21 million shs
ZYME Zymeworks	$12.47 +0.8%	$12.18	$8.32 ▼ $17.70	$867.63M	1.17	588,837 shs	2.15 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	0.00%	+2.54%	+12.04%	+37.50%	-12.32%
NTLA Intellia Therapeutics	0.00%	+3.91%	+28.32%	+18.46%	-58.27%
SYRE Spyre Therapeutics	0.00%	+1.40%	-2.12%	-15.16%	-34.93%
ZYME Zymeworks	0.00%	-0.08%	+9.87%	+0.81%	+48.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FHTX Foghorn Therapeutics	1.9663 of 5 stars	3.6	0.0	0.0	2.7	1.7	0.6
NTLA Intellia Therapeutics	4.6074 of 5 stars	4.3	3.0	4.7	1.3	2.5	0.6
SYRE Spyre Therapeutics	2.1352 of 5 stars	3.6	0.0	0.0	2.3	2.5	0.6
ZYME Zymeworks	1.9202 of 5 stars	3.5	1.0	0.0	1.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	150.52% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	249.04% Upside
SYRE Spyre Therapeutics	3.25	Buy	$53.40	250.85% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.00	68.40% Upside

Current Analyst Ratings Breakdown

Latest FHTX, SYRE, NTLA, and ZYME Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/20/2025	ZYME Zymeworks	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FHTX Foghorn Therapeutics	$22.60M	11.94	N/A	N/A	($0.82) per share	-5.90
NTLA Intellia Therapeutics	$57.88M	17.11	N/A	N/A	$8.56 per share	1.12
SYRE Spyre Therapeutics	$890K	1,030.86	N/A	N/A	$7.04 per share	2.16
ZYME Zymeworks	$93.38M	9.29	N/A	N/A	$6.63 per share	1.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.77	N/A	N/A	N/A	N/A	-77.46%	-41.06%	8/6/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.49	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	7/30/2025 (Estimated)

Latest FHTX, SYRE, NTLA, and ZYME Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.76	-$0.74	+$0.02	-$0.74	N/A	N/A
5/8/2025	N/A	ZYME Zymeworks	-$0.45	-$0.30	+$0.15	N/A	$20.65 million	$27.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FHTX Foghorn Therapeutics	N/A	3.16	3.16
NTLA Intellia Therapeutics	N/A	4.90	4.90
SYRE Spyre Therapeutics	N/A	8.06	8.06
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FHTX Foghorn Therapeutics	61.55%
NTLA Intellia Therapeutics	88.77%
SYRE Spyre Therapeutics	80.39%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
FHTX Foghorn Therapeutics	7.58%
NTLA Intellia Therapeutics	3.10%
SYRE Spyre Therapeutics	15.43%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
SYRE Spyre Therapeutics	73	60.28 million	50.98 million	Optionable
ZYME Zymeworks	460	69.58 million	67.56 million	Optionable

FHTX, SYRE, NTLA, and ZYME Headlines

Recent News About These Companies

Zymeworks Amends Warrant Agreement with EcoR1 Capital

June 27 at 4:59 PM | tipranks.com

ZYME - Zymeworks Inc Registered Shs Dividends - Morningstar

June 27 at 3:30 PM | morningstar.comM

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

June 25, 2025 | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus Price Target from Brokerages

June 24, 2025 | americanbankingnews.com

Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

June 20, 2025 | zacks.com

Rhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)

June 20, 2025 | marketbeat.com

Duncan Williams Asset Management LLC Buys Shares of 22,095 Zymeworks Inc. (NYSE:ZYME)

June 19, 2025 | marketbeat.com

Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500

June 18, 2025 | kalkinemedia.comK

SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME)

June 17, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 147,184 Shares of Zymeworks Inc. (NYSE:ZYME)

June 15, 2025 | marketbeat.com

Zymeworks (NYSE:ZYME) Shares Gap Down - Time to Sell?

June 13, 2025 | marketbeat.com

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

June 12, 2025 | seekingalpha.com

Bank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME)

June 12, 2025 | marketbeat.com

Wellington Management Group LLP Decreases Position in Zymeworks Inc. (NYSE:ZYME)

June 5, 2025 | marketbeat.com

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

June 4, 2025 | zacks.com

Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

June 2, 2025 | msn.com

Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC

June 2, 2025 | marketbeat.com

Voloridge Investment Management LLC Buys Shares of 43,708 Zymeworks Inc. (NYSE:ZYME)

May 31, 2025 | marketbeat.com

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

May 30, 2025 | endpts.comE

China's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract Cancer

May 30, 2025 | precisionmedicineonline.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX, SYRE, NTLA, and ZYME Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

$4.84 -0.02 (-0.41%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.84 0.00 (0.00%)

As of 06/27/2025 04:34 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics NASDAQ:NTLA

$9.56 -0.05 (-0.52%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.61 +0.05 (+0.51%)

As of 06/27/2025 07:59 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Spyre Therapeutics NASDAQ:SYRE

$15.22 -0.80 (-4.99%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$15.11 -0.11 (-0.72%)

As of 06/27/2025 07:35 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Zymeworks NYSE:ZYME

$12.47 +0.10 (+0.81%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$12.60 +0.14 (+1.08%)

As of 06/27/2025 07:04 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time